PCSK9 and venous thromboembolism: In a prespecified analysis of both ODYSSEY Outcomes [77] and Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) [78] clinical trials, they sought to find an association between venous thromboembolism (VTE) and Lp(a) levels and the influence of PCSK9 monoclonal antibodies of future VTE.